Janus Henderson Group PLC increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 15.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 285,035 shares of the medical equipment provider’s stock after buying an additional 38,283 shares during the period. Janus Henderson Group PLC owned 0.10% of Hologic worth $10,458,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of HOLX. Advisors Asset Management Inc. lifted its position in Hologic by 7.4% during the 2nd quarter. Advisors Asset Management Inc. now owns 16,602 shares of the medical equipment provider’s stock worth $753,000 after buying an additional 1,140 shares in the last quarter. KBC Group NV lifted its position in Hologic by 60.5% during the 2nd quarter. KBC Group NV now owns 34,855 shares of the medical equipment provider’s stock valued at $1,582,000 after purchasing an additional 13,138 shares during the period. Jennison Associates LLC acquired a new position in Hologic during the 2nd quarter valued at about $454,000. Marshall Wace North America L.P. acquired a new position in Hologic during the 2nd quarter valued at about $1,517,000. Finally, William Blair Investment Management LLC lifted its position in Hologic by 56.1% during the 2nd quarter. William Blair Investment Management LLC now owns 15,928 shares of the medical equipment provider’s stock valued at $723,000 after purchasing an additional 5,722 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

In related news, Director Elaine Ullian sold 9,282 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence M. Levy sold 9,596 shares of the stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The disclosure for this sale can be found here. Insiders sold a total of 28,833 shares of company stock worth $1,107,270 over the last quarter. 0.79% of the stock is currently owned by corporate insiders.

Shares of Hologic, Inc. (HOLX) opened at $43.37 on Tuesday. The firm has a market cap of $11,960.00, a P/E ratio of 16.43, a P/E/G ratio of 2.09 and a beta of 0.95. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. Hologic, Inc. has a 52-week low of $35.76 and a 52-week high of $46.80.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. Hologic’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the company posted $0.52 EPS. research analysts predict that Hologic, Inc. will post 2.12 earnings per share for the current fiscal year.

A number of research firms have issued reports on HOLX. Cowen upgraded shares of Hologic to a “buy” rating and set a $52.00 target price on the stock in a research report on Wednesday, December 20th. Needham & Company LLC restated a “buy” rating and set a $48.00 target price (up from $46.00) on shares of Hologic in a research report on Tuesday, December 5th. Goldman Sachs Group upgraded shares of Hologic from a “buy” rating to a “conviction-buy” rating and upped their target price for the company from $45.00 to $50.00 in a research report on Friday, December 8th. Piper Jaffray Companies restated a “buy” rating and set a $48.00 target price on shares of Hologic in a research report on Thursday, November 9th. Finally, Stifel Nicolaus restated a “buy” rating and set a $45.00 target price (down from $48.00) on shares of Hologic in a research report on Monday, October 9th. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $47.93.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/12/26/janus-henderson-group-plc-raises-position-in-hologic-inc-holx.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with Analyst Ratings Network's FREE daily email newsletter.